Preclinical proof-of-platform for our blood-brain barrier crossing technology’s transformative power is presented in a December 2022 publication from Janssen in Cell Press: Med, titled “Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.” The paper describes the MODEL platform components (termed transcytosis-enabling modules (TEMs) by the authors) that facilitate significant increases in brain exposure and efficient target clearance by antibodies across a range of CNS applications in vitro and in vivo.
A commentary on this publication, also published in the December 2022 Cell Press: Med, “A novel bispecific antibody able to pass the blood-brain barrier and therapeutically engage within the brain,” further elucidates the capabilities of our foundational platform.